Laurus Labs Limited — PPTs, 24-04-2025: Investor Presentation

**Financial Highlights:**

Laurus Labs reported revenues of ₹5,554 Cr for FY 2025, a 10% year-over-year increase, primarily driven by robust CDMO performance. Gross margins improved to 55.4%, reflecting a better product mix, while EBITDA surged 40% to ₹1,115 Cr with margins rising to 20.1%. Net profit skyrocketed 122% to ₹358 Cr, although operating cash flow saw a decline due to higher working capital needs. The company maintains a stable net debt at ₹2,693 Cr, with an overall debt-to-EBITDA ratio of 2.3x.

**Strategic Initiatives and Growth Drivers:**

The company expanded its capabilities with new R&D and manufacturing facilities, focusing on advanced modalities like gene therapy and biocatalysis. This includes significant investments in capacity expansion at its Vizag site. Laurus is strengthening partnerships with big pharma and enhancing its technology platform to reinforce its competitive advantage.

**Business Developments:**

Laurus has been actively negotiating contracts in the CDMO sector, underlining a growing pipeline. The CDMO segment's revenue rose by 42%, significantly contributing to the company's overall growth.

**Market Position and Competitive Advantage:**

With a diverse product offering and a solid market presence in the CDMO space, Laurus is well-positioned to capitalize on rising demand. The firm aims to leverage its expertise in small molecule and differentiated generic drug solutions.

**Investor Implications:**

With a positive outlook driven by strategic initiatives and improved financial metrics, investors should consider Laurus as a strong player in the pharmaceutical sector, especially given the increasing demand for integrated and specialized capabilities in drug manufacturing. Risks remain, particularly in the API market, which has shown softness. However, the robust expansion plans signal potential long-term growth.